FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283205965> ?p ?o ?g. }

• W4283205965 abstract "Peritoneal fibrosis (PF), a common complication in patients receiving peritoneal dialysis (PD), is primarily caused by the epithelial-mesenchymal transition (EMT) of human peritoneal mesothelial cells (HPMCs). PF is the main reason for patients on PD to withdraw from PD. Effective treatment is unavailable for this complication at present. Elabela (ELA) is a polypeptide hormone secreted by the vascular endothelium and kidney. Peptide hormones ELA and apelin (APLN) have various protective effects on the cardiovascular and urinary systems and have potential therapeutic effects on organ fibrosis. ELA and APLN are less studied in PD population. Here, we aimed to investigate the clinical significance of ELA in patients on PD and to evaluate the therapeutic effect of ELA on EMT of HPMCs. Compared with those in patients with stage 5 chronic kidney disease who are not on dialysis, serum ELA levels in patients on PD increased with the improvement of residual renal function at PD duration <36 months and decreased to pre-dialysis levels at PD duration ≥36 months, suggesting that dialysis duration is the main risk factor affecting serum ELA levels in patients on PD. In addition, serum APLN levels decreased in the early stage of PD and recovered to the pre-dialysis level with the prolongation of dialysis time. Notably, serum APLN levels were positively correlated with dialysis duration in patients undergoing PD. To establish the EMT model, we stimulated HPMCs using transforming growth factor-beta 1 (TGF-β1) in cell experiments performed in vitro. ELA-32 treatment reversed the TGF-β1-induced reduction in the expression of the epithelial cell marker and suppressed the expression of mesenchymal cell markers by inhibiting the phosphorylation of SMAD2/3, ERK1/2, and AKT. Therefore, our findings imply that ELA-32 can interfere with the EMT of HPMCs by inhibiting the activation of the TGF-β/SMAD2/3, ERK1/2, and AKT pathways, providing novel insights on the potential therapeutic use of ELA for treating PD-related PF." @default.
• W4283205965 created "2022-06-22" @default.
• W4283205965 creator A5007534648 @default.
• W4283205965 creator A5009846821 @default.
• W4283205965 creator A5017218508 @default.
• W4283205965 creator A5034631079 @default.
• W4283205965 creator A5044259723 @default.
• W4283205965 creator A5050792667 @default.
• W4283205965 creator A5058869908 @default.
• W4283205965 date "2022-06-21" @default.
• W4283205965 modified "2023-10-18" @default.
• W4283205965 title "Elabela Attenuates the TGF-β1-Induced Epithelial-Mesenchymal Transition of Peritoneal Mesothelial Cells in Patients Receiving Peritoneal Dialysis" @default.
• W4283205965 cites W1562765779 @default.
• W4283205965 cites W1989706089 @default.
• W4283205965 cites W2013824152 @default.
• W4283205965 cites W2052395944 @default.
• W4283205965 cites W2054035015 @default.
• W4283205965 cites W2060660919 @default.
• W4283205965 cites W2061895592 @default.
• W4283205965 cites W2087458930 @default.
• W4283205965 cites W2097603228 @default.
• W4283205965 cites W2114091927 @default.
• W4283205965 cites W2136081838 @default.
• W4283205965 cites W2152509794 @default.
• W4283205965 cites W2185906984 @default.
• W4283205965 cites W2267248673 @default.
• W4283205965 cites W2296782701 @default.
• W4283205965 cites W2401854918 @default.
• W4283205965 cites W2469939151 @default.
• W4283205965 cites W2583089302 @default.
• W4283205965 cites W2771070124 @default.
• W4283205965 cites W2982245807 @default.
• W4283205965 cites W3002000652 @default.
• W4283205965 cites W3044789329 @default.
• W4283205965 cites W3044866655 @default.
• W4283205965 cites W3084886754 @default.
• W4283205965 cites W3109174387 @default.
• W4283205965 cites W3119344524 @default.
• W4283205965 cites W3174892273 @default.
• W4283205965 cites W3188704765 @default.
• W4283205965 cites W3197352280 @default.
• W4283205965 cites W3203747950 @default.
• W4283205965 cites W4205130283 @default.
• W4283205965 cites W4206157609 @default.
• W4283205965 cites W4210571040 @default.
• W4283205965 doi "https://doi.org/10.3389/fphar.2022.890881" @default.
• W4283205965 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35800446" @default.
• W4283205965 hasPublicationYear "2022" @default.
• W4283205965 type Work @default.
• W4283205965 citedByCount "0" @default.
• W4283205965 crossrefType "journal-article" @default.
• W4283205965 hasAuthorship W4283205965A5007534648 @default.
• W4283205965 hasAuthorship W4283205965A5009846821 @default.
• W4283205965 hasAuthorship W4283205965A5017218508 @default.
• W4283205965 hasAuthorship W4283205965A5034631079 @default.
• W4283205965 hasAuthorship W4283205965A5044259723 @default.
• W4283205965 hasAuthorship W4283205965A5050792667 @default.
• W4283205965 hasAuthorship W4283205965A5058869908 @default.
• W4283205965 hasBestOaLocation W42832059651 @default.
• W4283205965 hasConcept C118131993 @default.
• W4283205965 hasConcept C121608353 @default.
• W4283205965 hasConcept C126322002 @default.
• W4283205965 hasConcept C126894567 @default.
• W4283205965 hasConcept C134018914 @default.
• W4283205965 hasConcept C2778653478 @default.
• W4283205965 hasConcept C2779013556 @default.
• W4283205965 hasConcept C2779056158 @default.
• W4283205965 hasConcept C2779978075 @default.
• W4283205965 hasConcept C2780559512 @default.
• W4283205965 hasConcept C2908647359 @default.
• W4283205965 hasConcept C71315377 @default.
• W4283205965 hasConcept C71924100 @default.
• W4283205965 hasConcept C76419328 @default.
• W4283205965 hasConcept C90924648 @default.
• W4283205965 hasConcept C99454951 @default.
• W4283205965 hasConceptScore W4283205965C118131993 @default.
• W4283205965 hasConceptScore W4283205965C121608353 @default.
• W4283205965 hasConceptScore W4283205965C126322002 @default.
• W4283205965 hasConceptScore W4283205965C126894567 @default.
• W4283205965 hasConceptScore W4283205965C134018914 @default.
• W4283205965 hasConceptScore W4283205965C2778653478 @default.
• W4283205965 hasConceptScore W4283205965C2779013556 @default.
• W4283205965 hasConceptScore W4283205965C2779056158 @default.
• W4283205965 hasConceptScore W4283205965C2779978075 @default.
• W4283205965 hasConceptScore W4283205965C2780559512 @default.
• W4283205965 hasConceptScore W4283205965C2908647359 @default.
• W4283205965 hasConceptScore W4283205965C71315377 @default.
• W4283205965 hasConceptScore W4283205965C71924100 @default.
• W4283205965 hasConceptScore W4283205965C76419328 @default.
• W4283205965 hasConceptScore W4283205965C90924648 @default.
• W4283205965 hasConceptScore W4283205965C99454951 @default.
• W4283205965 hasFunder F4320324095 @default.
• W4283205965 hasLocation W42832059651 @default.
• W4283205965 hasLocation W42832059652 @default.
• W4283205965 hasLocation W42832059653 @default.
• W4283205965 hasOpenAccess W4283205965 @default.
• W4283205965 hasPrimaryLocation W42832059651 @default.
• W4283205965 hasRelatedWork W1997759048 @default.
• W4283205965 hasRelatedWork W200794292 @default.
• W4283205965 hasRelatedWork W2010645160 @default.

• next